Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review. (April 2022)

• Record Type: Journal Article
• Authors: Juarez-Garcia, Ariadna; Sharma, Ruchika; Hunger, Matthias; Kayaniyil, Sheena; Penrod, John R.; Chouaïd, Christos
• Is Part Of: Lung cancer. Volume 166(2022)
• Page Start: 205
• Page End: 220
• Publication Date: 2022-04
• Subjects: ATE atezolizumab -- BSC best supportive care -- CI confidence interval -- CNS central nervous system -- DUR durvalumab -- ECOG PS Eastern Co-operative Oncology Group performance status -- EC European Commission -- EGFR epidermal growth factor receptor -- FDA Food and Drug Administration -- HR hazard ratio -- ICI immune checkpoint inhibitors -- IO immunotherapy -- NIV nivolumab -- NSCLC non-small cell lung cancer -- OS overall survival -- PD-L1 programmed death-ligand 1 -- PD-1 programmed death receptor-1 -- PEM pembrolizumab -- PFS progression-free survival -- PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses -- PS performance status -- RCT randomized controlled trials -- RWE real-world evidence -- SLR systematic literature review; NSCLC -- Real-world evidence -- Immunotherapy -- Overall survival -- Effectiveness -- Nivolumab; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2022.03.008
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Real-world studies show how immunotherapy benefits translate into clinical practice. This systematic review includes 66 studies with 35, 103 advanced NSCLC patients. The pooled estimate for 1-year (2-year) survival rate with nivolumab is 46% (28%). No significant difference in survival between elderly and non-elderly patients. Poor performance status is associated with shorter survival outcomes for nivolumab. Abstract: Background: Clinical trials have shown immunotherapy (IO) to be more effective than chemotherapy in pre-treated, advanced non-small cell lung cancer (NSCLC). However, there is a lack of understanding of its effectiveness in clinical practice, and among patient groups that are often underrepresented in trials. We aimed to summarize the existing real-world evidence (RWE) on the survival outcomes of IO in second- or higher line in advanced NSCLC. Methods: We conducted a systematic review of real-world observational studies that reported overall survival (OS) estimates with IO, primarily nivolumab, pembrolizumab or atezolizumab, in adult, previously treated advanced or recurrent NSCLC patients. Meta-analysis was conducted using random-effect models to pool 1- and 2-year OS rates across studies. Additional subgroups were examined among patients treated with IO, including the elderly, those with poor performance status (PS) and those exhibiting metastasis. Results: In total, 66 studies were included, of which 46 (70%) included a nivolumab-specific study arm. Pooled 1-year and 2-year OS rates with nivolumab monotherapy were 45.6% (95% CI; 43.4–47.8) and 28.0% (95% CI; 24.8–31.4), respectively, compared to 43.9% (95% CI; 39.1–48.8) and 20.4% (95% CI; 14.7–27.6) in the mixed immune checkpoint inhibitors (ICI) group. OS rates with nivolumab were slightly lower in elderly compared to non-elderly populations. Poor PS was associated with worse survival rates, with a pooled one-year OS estimate of 27.1% in PS ≥ 2 vs 51.6% in PS < 2. The pooled 2-year OS rate with nivolumab in patients with and without brain metastases was 22.1% and 26.1% respectively, and this difference was significant in 36% of individual studies. Conclusions: While the OS benefits of IO seen in real-world studies among pre-treated, advanced NSCLC patients are consistent with pivotal clinical trials, these tend to vary for the more vulnerable patient groups, such as patients with poor PS, which are often excluded from trials. Further research is needed to investigate findings in patients with brain and liver metastases.